Get started
Author

Lokesh Jain

Combination Targeted Therapy With Sorafenib and Bevacizumab Results in Enhanced Toxicity and Antitumor Activity
2008 · Nilofer S. Azad, Edwin M. Posadas, et al. · Journal of Clinical Oncology · 332
Pembrolizumab Exposure–Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance
2018 · David C. Turner, Anna G. Kondic, et al. · Clinical Cancer Research · 217
Implications of Obesity for Drug Therapy: Limitations and Challenges
2011 · R Jain, S M Chung, et al. · Clinical Pharmacology & Therapeutics · 210
A Phase II Clinical Trial of Sorafenib in Androgen-Independent Prostate Cancer
2008 · William L. Dahut, Charity Scripture, et al. · Clinical Cancer Research · 182
The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors
2009 · Lokesh Jain, Craig A. Vargo, et al. · Molecular Cancer Therapeutics · 168
PDF
A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation
2020 · Mallika Lala, Tommy Ruosi Li, et al. · European Journal of Cancer · 164
Hand-Foot Skin Reaction Increases with Cumulative Sorafenib Dose and with Combination Anti-Vascular Endothelial Growth Factor Therapy
2009 · Nilofer S. Azad, Jeanny B. Aragon-Ching, et al. · Clinical Cancer Research · 145
PDF
A Phase I Study of PF-04929113 (SNX-5422), an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Patients with Refractory Solid Tumor Malignancies and Lymphomas
2011 · Arun Rajan, Ronan J. Kelly, et al. · Clinical Cancer Research · 143
PDF
Population pharmacokinetic analysis of sorafenib in patients with solid tumours
2011 · Lokesh Jain, Sukyung Woo, et al. · British Journal of Clinical Pharmacology · 142
PDF
Efficacy of Zenocutuzumab in NRG1 Fusion–Positive Cancer
2025 · Alison M. Schram, Koichi Goto, et al. · New England Journal of Medicine · 140
PDF
Sorafenib Is an Inhibitor of UGT1A1 but Is Metabolized by UGT1A9: Implications of Genetic Variants on Pharmacokinetics and Hyperbilirubinemia
2012 · Cody J. Peer, Tristan M. Sissung, et al. · Clinical Cancer Research · 132
PDF
Final analysis of a phase II trial using sorafenib for metastatic castration‐resistant prostate cancer
2009 · Jeanny B. Aragon‐Ching, Lokesh Jain, et al. · British Journal of Urology · 118
Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib
2010 · Lokesh Jain, Tristan M Sissung, et al. · Journal of Experimental & Clinical Cancer Research · 102
PDF
Innovation at the Intersection of Clinical Trials and Real‐World Data Science to Advance Patient Care
2018 · Brandon Swift, Lokesh Jain, et al. · Clinical and Translational Science · 64
PDF
Development of a rapid and sensitive LC–MS/MS assay for the determination of sorafenib in human plasma
2007 · Lokesh Jain, Erin R. Gardner, et al. · Journal of Pharmaceutical and Biomedical Analysis · 64
Pharmacokinetic Assessment in Patients Receiving Continuous RRT
2014 · Thomas D. Nolin, George R. Aronoff, et al. · Clinical Journal of the American Society of Nephrology · 59
Immunogenicity of pembrolizumab in patients with advanced tumors
2019 · Marianne J. H. van Vugt, Julie A. Stone, et al. · Journal for ImmunoTherapy of Cancer · 57
PDF
Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study
2018 · Michael B. Atkins, F. Stephen Hodi, et al. · Clinical Cancer Research · 57
A six-weekly (Q6W) dosing schedule for pembrolizumab based on an exposure-response (E-R) evaluation using modeling and simulation.
2018 · Mallika Lala, Mengyao Li, et al. · Journal of Clinical Oncology · 41
Lack of Association Between Excretion of Sorafenib in Sweat and Hand‐Foot Skin Reaction
2009 · Lokesh Jain, Erin R. Gardner, et al. · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · 38
Pivotal Dose of Pembrolizumab: A Dose‐Finding Strategy for Immuno‐Oncology
2021 · Tommy R. Li, Manash Chatterjee, et al. · Clinical Pharmacology & Therapeutics · 33
Abstract CT042: Pembrolizumab 400 mg Q6W dosing: First clinical outcomes data from Keynote-555 cohort B in metastatic melanoma patients
2020 · Mallika Lala, Omobolaji Akala, et al. · Cancer Research · 26
Updated efficacy and safety of KEYNOTE-224: A phase II study of pembrolizumab (pembro) in patients with advanced hepatocellular carcinoma (HCC).
2020 · Masatoshi Kudo, Richard S. Finn, et al. · Journal of Clinical Oncology · 20
PDUFA VI: It Is Time to Unleash the Full Potential of Model‐Informed Drug Development
2018 · Lokesh Jain, Nitin Mehrotra, et al. · CPT Pharmacometrics & Systems Pharmacology · 20
Population pharmacokinetic analyses for belzutifan to inform dosing considerations and labeling
2023 · Dhananjay D. Marathe, Petra M. Jauslin, et al. · CPT Pharmacometrics & Systems Pharmacology · 17
PDF
Works count: 89
Citation count: 2,876
H-index: 22
I10-index: 33
Year
Topic
Type